Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1

Abstract excerpt

Advances in DNA sequencing technologies have provided exceptional detail of the genomic and epigenomic landscapes in acute myeloid leukemia (AML) 1 , 2 . A key insight emerging from this data is that proteins involved in epigenetic processes are early drivers of the cancer phenotype and may be attractive drug targets 2 , 3 . Mutations in tet methylcytosine dioxygenase 2 ( TET2 ) occur in ~10% of patients with AML...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Lymphoblastic Leukemia research
• Share to Acute Myeloid Leukemia Research
• Share to Folate and B Vitamins Research